National Institute for Health and Care Excellence (NICE)
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. This updates a previously published guideline summary.
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer.
Recommendations
Major Recommendations
Paclitaxel in combination with platinum or as monotherapy is recommended within its marketing authorisation as an option for treating recurrent ovarian cancer.
Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy is recommended within its marketing authorisation as an option for treating recurrent ovarian cancer.
PLDH in combination with platinum is recommended as an option for treating recurrent ovarian cancer.1,2
The following are not recommended within their marketing authorisations for treating the first recurrence of platinum-sensitive ovarian cancer:
- Gemcitabine in combination with carboplatin
- Trabectedin in combination with PLDH
- Topotecan
The appraisal committee was unable to make recommendations on the use of these technologies for treating platinum-sensitive ovarian cancer beyond the first recurrence.
Topotecan is not recommended within its marketing authorisation for treating recurrent platinum-resistant or platinum-refractory ovarian cancer.
People whose treatment with gemcitabine in combination with carboplatin, trabectedin in combination with PLDH, or topotecan is not recommended in this National Institute for Health and Care Excellence (NICE) guidance, but was started within the National Health Service (NHS) before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.
Footnotes
1At the time of publication (April 2016), PLDH (Caelyx) in combination with platinum did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Good practice in prescribing medicines – guidance for doctors for further information.
2The use of PLDH (Caelyx) in combination with platinum is outside the terms of the marketing authorisation for Caelyx. Consequently the statutory funding requirement does not apply to this recommendation. NICE received a remit to appraise this combination under Regulation 5 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 
.
.Clinical Algorithm(s)
None provided
Scope
Disease/Condition(s)
Recurrent ovarian cancer
Guideline Category
Assessment of Therapeutic Effectiveness
Treatment
Clinical Specialty
Obstetrics and Gynecology
Oncology
Intended Users
Advanced Practice Nurses
Nurses
Physician Assistants
Physicians
Guideline Objective(s)
To assess the clinical effectiveness and cost-effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride (PLDH), paclitaxel, trabectedin and gemcitabine for the treatment of advanced, recurrent ovarian cancer
Target Population
Women with ovarian cancer that has recurred after first-line (or subsequent) platinum-based chemotherapy or that is refractory to platinum-based chemotherapy
Interventions and Practices Considered
- Paclitaxel alone or in combination with platinum chemotherapy
- Pegylated liposomal doxorubicin hydrochloride (PLDH) alone or in combination with platinum chemotherapy
Note: The following were considered but not recommended: gemcitabine, trabectedin in combination with PLDH, topotecan.
Major Outcomes Considered
- Clinical effectiveness
- Overall survival (OS)
- Progression-free survival (PFS)
- Overall response rate (ORR)
- Adverse effects of treatment
- Health-related quality of life (HRQoL)
- Time to progression (TTP)
- Cost-effectiveness
Methodology
Methods Used to Collect/Select the Evidence
Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Searches of Unpublished Data
Description of Methods Used to Collect/Select the Evidence
Note from the National Guideline Clearinghouse (NGC): The National Institute for Health and Care Excellence (NICE) commissioned an independent academic centre to perform a systematic literature review on the technology considered in this appraisal and prepare an assessment report. The Assessment Report for this technology appraisal was prepared by BMJ-Technology Assessment Group (BMJ TAG) (see the "Availability of Companion Documents" field).
Assessment of Clinical Effectiveness
Methods for Reviewing Effectiveness
Identification of Studies
The literature search for this review was designed to update and expand the systematic search carried out in Technology Appraisal 91 (TA91), which evaluated the clinical and cost-effectiveness of topotecan, pegylated liposomal doxorubicin hydrochloride (PLDH), and paclitaxel. Medical Subject Headings (MeSH) and text terms for ovarian cancer, topotecan, PLDH, and paclitaxel were taken from the search strategy presented in TA91, and text terms added for the interventions trabectedin and gemcitabine. To ensure capture of all potentially relevant studies to inform a network meta-analysis (NMA), the decision was taken not to restrict the start date of the update search to the end date of the search (2004) reported in TA91.
As a result of the large number of studies retrieved from the scoping search, the decision was taken to implement search filters for randomised controlled trials (RCTs). Filters developed and validated by Scottish Intercollegiate Guidelines Network were used. The identified RCTs facilitated construction of three distinct networks for the outcomes of overall survival (OS) and progression-free survival (PFS) for both the platinum-sensitive (two networks) and platinum-resistant/refractory (1 network) subgroups. In an attempt to identify a study to link the discrete networks for the platinum-sensitive subgroup, the retrieved abstracts were re-examined to consider interventions outside the scope of this review. Due to time constraints, the decision was taken not to search for non-randomised trials. Bibliographies of previous reviews and retrieved articles were searched for additional studies. Clinical trial registries were also searched to identify planned, ongoing and finalised clinical trials of interest. In addition, clinical experts were contacted with a request for information on any additional studies of which they had knowledge. The manufacturers' submissions (MSs) were assessed for unpublished data. Although the protocol stipulates that the Index to Scientific and Technical Proceedings would be searched to identify relevant conference proceedings, due to time constraints this was not undertaken. However, based on the conference abstracts retrieved from the search of the pre-specified electronic databases, the Technology Assessment Group (TAG) considers it likely that the key conference abstracts have been identified. Conference abstracts that were reviewed and found not to report additional results to those presented in the relevant full publication were excluded.
Electronic databases were initially searched on 18 January 2013 and results uploaded into Reference Manager Version 11.0 and deduplicated. An update search was carried out on 23 May 2013. No papers or abstracts published after this date were included in the review. Full details of the strategies are presented in Appendix 1 of the Assessment Report.
Titles and abstracts returned by the search strategy were examined independently by two researchers and screened for possible inclusion. Disagreements were resolved by discussion, or involvement of a third reviewer in cases where consensus could not be achieved. Full texts of potentially relevant studies were ordered. Full publications were assessed independently by two reviewers for inclusion or exclusion against prespecified criteria, with disagreements resolved by discussion or input from a third reviewer when consensus could not be achieved.
Inclusion and Exclusion Criteria
For the review of clinical effectiveness, only RCTs were considered for inclusion in the review. Systematic reviews and non-randomised studies were excluded, as were studies that considered drugs administered as "maintenance therapy" following directly on from first-line therapy without evidence of disease progression. Inclusion criteria were based on the decision problem outlined in Section 3.1 of the Assessment Review (presented as a whole in the table below). No restrictions were imposed on language or date of publication. Reference lists of identified systematic reviews were used as a source of potential additional RCTs, as well as a resource to compare studies retrieved from the systematic literature search.
Table: Inclusion Criteria (Based on the Decision Problem) for Studies Evaluating Clinical Effectiveness
| Inclusion Criteria | |
|---|---|
| Study Design | Randomised controlled trials (RCTs) |
| Population | People with ovarian cancer that has recurred after first-line (or subsequent) platinum-based chemotherapy or is refractory to platinum-based chemotherapy |
| Interventions | For people with platinum-sensitive ovarian cancer:
|
| Comparators | For people with platinum-sensitive ovarian cancer:
|
Quantity and Quality of Research Available
The searches retrieved a total of 5,993 records (post deduplication) that were of possible relevance to the review (see Figure 3 in the Assessment Report). These were screened and 104 full references were ordered. Of these 5 had to be cancelled because they were unobtainable. Of the full references evaluated, 28 papers describing 16 studies were included in the review.
The full list of studies included in the review is given in Table 18 of the Assessment Report, while a list of the papers screened but subsequently excluded (with reasons for exclusion) from the review is presented in Appendix 3 of the Assessment Report.
Assessment of Cost-effectiveness
Technology Assessment Group Systematic Review of Existing Cost-effectiveness Evidence
A systematic review was carried out in December 2012 to identify relevant published economic evaluations to support the development of this multiple technology appraisal (MTA). The following databases were searched:
- MEDLINE (Ovid)
- EMBASE (Ovid)
- Health Technology Assessment database (HTA)
- NHS Economic Evaluations Database (NHS EED)
The search strategy for MEDLINE and EMBASE combined terms capturing the interventions and comparators of interest (topotecan, PLDH, paclitaxel, trabectedin, gemcitabine, best supportive care, bevacizumab, carboplatin, cisplatin, and etoposide); the target condition (ovarian cancer); and terms to capture economic evaluations. As this MTA is in part an update of TA91, in which a systematic review was carried out (search date of April 2004) to evaluate the cost-effectiveness of topotecan, PLDH, and paclitaxel, searches for these interventions were carried out with a date limit of 2004. Databases were searched from inception for gemcitabine and trabectedin. The search strategy for HTA and NHS EED combined terms for the target condition (ovarian cancer) with no further limits. Full details of the search terms are presented in Appendix 5 of the Assessment Report.
In addition to searches of the above databases the following sources of potentially relevant publications were explored:
- Experts in the field were contacted with a request for details of relevant published and unpublished studies of which they may have knowledge.
- The NICE Web site was searched for any recently published Technology Appraisals in ovarian cancer that had not already been identified via the database searches.
- Reference lists of key identified studies were reviewed for any potentially relevant studies.
No restrictions on language or setting were applied to any of the searches. The titles and abstracts of papers identified through the searches were independently assessed for inclusion by two health economists using the criteria outlined in the table below.
Table: Inclusion and Exclusion Criteria for the Economic Evaluation Systematic Review
| Inclusion Criteria | Exclusion Criteria |
|---|---|
|
|
The systematic review was updated in May 2013 whilst the report was under peer review. The search strategy remained the same as outlined above; however, results were limited from December 4th 2012 to May 21st 2013 in order to identify only additional relevant studies.
A total of 842 papers were identified from the December 2012 search (see Figure 14 in the Assessment Report). Of these papers, 740 were excluded on the basis of title and abstract. A total of 102 papers were therefore identified as potentially relevant and were ordered for full review. Of the 102 ordered papers, 59 were excluded following review of the full paper. For a description of the reason for exclusion of the ordered papers, see Appendix 6 of the Assessment Report. A total of 43 papers were identified as economic evaluations from the December 2012 search.
A further 91 papers were identified from the updated search in May 2013. Of these, 90 were excluded on the basis of title and abstract, with one paper identified as potentially relevant and ordered for full review. Additionally, two relevant NICE TAs were identified from the NICE Web site and were reviewed in full: TA284 and TA285.
Number of Source Documents
Clinical Effectiveness
Of the full references evaluated, 28 papers describing 16 studies were included in the review.
Cost-effectiveness
- Of the 46 economic evaluation studies identified from the December 2012 (43 papers) and May 2013 (three papers) searches, 21 related specifically to recurrent ovarian cancer (see Table 89 of the Assessment Report). These 21 studies were considered by the TAG to be the most relevant to this MTA, and were extracted in full; the remaining included papers are presented as short summaries (see Appendix 7 of the Assessment Report).
- The Assessment Group and one of the manufacturers submitted economic models.
Methods Used to Assess the Quality and Strength of the Evidence
Expert Consensus
Rating Scheme for the Strength of the Evidence
Not applicable
Methods Used to Analyze the Evidence
Meta-Analysis
Review of Published Meta-Analyses
Systematic Review with Evidence Tables
Description of the Methods Used to Analyze the Evidence
Note from the National Guideline Clearinghouse (NGC): The National Institute for Health and Care Excellence (NICE) commissioned an independent academic centre to perform a systematic literature review on the technology considered in this appraisal and prepare an assessment report. The Assessment Report for this technology appraisal was prepared by BMJ-Technology Assessment Group (BMJ TAG) (see the "Availability of Companion Documents" field).
Assessment of Clinical Effectiveness
Methods for Reviewing Effectiveness
Data Abstraction Strategy
Data pertaining to study design, methodology, baseline characteristics, and clinical outcomes efficacy were extracted by two reviewers into a standardised data extraction form and validated by a second. Discrepancies were resolved by discussion when necessary. Authors of reports published as meeting abstracts only, where insufficient methodological details were reported to allow critical appraisal of study quality were contacted with a request for additional information. If no additional information was obtained, the studies were excluded. Data extraction forms for the included studies are provided in Appendix 2 of the Assessment Report.
Critical Appraisal Strategy
The quality of the clinical effectiveness data was assessed by two independent reviewers and checked for agreement. The study quality was assessed according to recommendations by the National Health Service (NHS) Centre for Reviews and Dissemination and Cochrane Handbook for Systematic Reviews of Interventions and recorded using the Cochrane Risk of Bias Tool.
Methods of Data Synthesis
Details of results on clinical effectiveness and quality assessment for each included study are presented in structured tables and as a narrative summary. The possible effects of study quality on the clinical effectiveness data and review findings are discussed. The 16 randomised controlled trials (RCTs) identified evaluated 14 different pair-wise comparisons. Therefore, there were insufficient data for most comparisons to carry out a standard pair-wise meta-analysis. However, the Technology Assessment Group (TAG) determined that the data identified were sufficiently homogenous to investigate comparative effectiveness of interventions via a network meta-analysis (NMA). The methods used for the NMA followed the guidance described in the NICE Decisions Support Unit's (DSU's) Technical Support Documents (TSDs) for Evidence Synthesis. In essence, an NMA assumes that each trial included in the network could have potentially included all treatments of interest but that some of these treatments are missing completely at random (MCAR). To illustrate this further, in a simple indirect comparison of three treatments A, B and C, the trials of A versus B and of B versus C are assumed to have been potentially trials of A versus B versus C but where one arm from each trial is MCAR. In this example, an estimate of the relative treatment effect of A versus C can be inferred using treatment B as a common comparator.
The TAG conducted an NMA for each network using a Bayesian Markov Chain Monte Carlo (MCMC) simulation in WinBUGS. The following were implemented for each analysis:
- Uniform priors (also called "flat" priors) were used.
- All outcomes were considered independent. For example, while overall survival (OS) and progression-free survival (PFS) might be correlated in advanced ovarian cancer, the degree of correlation is unlikely to be derived from summary trial estimates provided in published papers. As such, in the absence of individual patient data (IPD), the TAG took the pragmatic approach of assuming all efficacy and safety outcomes were independent.
- Results for all efficacy outcomes analysed were based on 50,000 iterations after a "burn in" of 30,000 iterations. For safety outcomes all analyses had a "burn in" of 30,000 iterations, with results based on 100,000 iterations.
- Summary effect estimates for OS and PFS were hazard ratios (HRs), while overall response rate (ORR) and all safety outcomes used odds ratios (ORs) as summary effect estimates.
- As a result of disparity in HRs reported in the identified trials, in terms of unadjusted HRs versus adjusted HRs, together with variation in adjustment factors, for consistency the TAG used only unadjusted HRs in the NMA.
- Any results taken forward into the economic model used the posterior sampling to retain the correlation between parameter estimates caused by their joint estimation from a single dataset.
However, the ability of the TAG to conduct NMAs was limited by the low number of trials identified (typically only one trial per treatment comparison).
See Section 4.1.5 of the Assessment Report for constraints imposed by the limited number of available trials. See Section 4 of the Assessment Report for additional information on clinical evidence analysis.
Cost-effectiveness
Independent Economic Assessment
As no single published study, or manufacturer's submission, simultaneously compared the cost-effectiveness of treatments relevant to the scope of this multiple technology appraisal (MTA), the TAG carried out an independent assessment and developed a de novo economic analysis.
Model Structure
The model structure employed by the TAG, to facilitate a comparison of the cost-effectiveness of the interventions and comparators outlined for this MTA, is derived from the cohort model developed in TA91 (see Figure 25 of the Assessment Report).
The TAG elected to use a cohort model approach rather than individual patient modelling. This approach was considered to be the most appropriate because, with the exception of platinum-free interval (PFI), there is limited evidence of the effect of individual patient characteristics/history on disease course. Furthermore, data were not available at a sufficiently disaggregated level in order to model at the individual level.
To capture the full costs and benefits associated with therapies for recurrent ovarian cancer, a lifetime time horizon was considered to be appropriate. In the base case analysis this is set as 15 years, because at this time point, over 99.9% of patients within the model have died. Furthermore, as per the NICE reference case, costs and benefits are discounted at a rate of 3.5% per annum, and an NHS and Personal Social Services (PSS) perspective was considered. The time horizon and discount rates used have been varied in sensitivity analysis.
See section 5 of the Assessment Report for additional information on cost-effectiveness analysis.
Methods Used to Formulate the Recommendations
Expert Consensus
Description of Methods Used to Formulate the Recommendations
Considerations
Technology appraisal recommendations are based on a review of clinical and economic evidence.
Technology Appraisal Process
The National Institute for Health and Care Excellence (NICE) invites 'consultee' and 'commentator' organisations to take part in the appraisal process. Consultee organisations include national groups representing patients and carers, the bodies representing health professionals, and the manufacturers of the technology under review. Consultees are invited to submit evidence during the appraisal and to comment on the appraisal documents.
Commentator organisations include manufacturers of the products with which the technology is being compared, the National Health Service (NHS) Quality Improvement Scotland and research groups working in the area. They can comment on the evidence and other documents but are not asked to submit evidence themselves.
NICE then commissions an independent academic centre to review published evidence on the technology and prepare an 'assessment report'. Consultees and commentators are invited to comment on the report. The assessment report and the comments on it are then drawn together in a document called the evaluation report.
An independent Appraisal Committee then considers the evaluation report. It holds a meeting where it hears direct, spoken evidence from nominated clinical experts, patients and carers. The Committee uses all the evidence to make its first recommendations, in a document called the 'appraisal consultation document' (ACD). NICE sends all the consultees and commentators a copy of this document and posts it on the NICE Web site. Further comments are invited from everyone taking part.
When the Committee meets again it considers any comments submitted on the ACD; then it prepares its final recommendations in a document called the 'final appraisal determination' (FAD). This is submitted to NICE for approval.
Consultees have a chance to appeal against the final recommendations in the FAD. If there are no appeals, the final recommendations become the basis of the guidance that NICE issues.
Who Is on the Appraisal Committee?
NICE technology appraisal recommendations are prepared by an independent committee. This includes health professionals working in the NHS and people who are familiar with the issues affecting patients and carers. Although the Appraisal Committee seeks the views of organisations representing health professionals, patients, carers, manufacturers and government, its advice is independent of any vested interests.
Rating Scheme for the Strength of the Recommendations
Not applicable
Cost Analysis
Summary of Appraisal Committee's Key Conclusions
Availability and Nature of Evidence
The company for trabectedin submitted cost-effectiveness evidence as part of its submission.
The assessment group developed a de novo model.
Uncertainties Around and Plausibility of Assumptions and Inputs in the Economic Model
There was uncertainty around estimates generated by the assessment group's network meta-analyses that were incorporated into the model. The committee noted that no evidence was available for gemcitabine plus carboplatin, topotecan, and trabectedin plus pegylated liposomal doxorubicin hydrochloride (PLDH) for treating second and subsequent recurrences of ovarian cancer in women with platinum-sensitive disease. The recommendations are therefore limited to a first recurrence of ovarian cancer and do not stop clinicians and patients from considering these treatments for second or subsequent recurrences of platinum-sensitive ovarian cancer.
Incorporation of Health-related Quality-of-Life Benefits and Utility Values. Have Any Potential Significant and Substantial Health-related Benefits Been Identified That Were Not Included in the Economic Model, and How Have They Been Considered?
The committee did not draw any specific conclusions about the health-related quality-of-life benefits and utility values.
Are There Specific Groups of People for Whom the Technology Is Particularly Cost Effective?
None was identified.
What Are the Key Drivers of Cost-effectiveness?
The incremental cost-effectiveness ratio (ICER) estimates were most sensitive to the relative effect of treatment on overall survival.
Most Likely Cost-effectiveness Estimate (Given as an ICER)
For women with platinum-sensitive recurrent ovarian cancer, the committee agreed that:
- The ICER for paclitaxel plus PLDH compared with platinum alone was approximately £24,400 per quality-adjusted life year (QALY) gained.
- PLDH plus platinum was dominated by paclitaxel plus platinum in the fully incremental analysis but the committee accepted that the ICER for PLDH plus platinum compared with platinum alone was approximately £30,200 per QALY gained and it could also be considered cost effective.
- For women who cannot have platinum treatment, the ICER for PLDH monotherapy compared with paclitaxel monotherapy was approximately £23,700 per QALY gained.
- Gemcitabine plus carboplatin was extendedly dominated and excluded from the fully incremental analysis. The committee agreed that the ICER for gemcitabine plus carboplatin compared with platinum alone was £114,000 per QALY gained.
- The ICER for trabectedin plus PLDH compared with PLDH alone, as estimated by the assessment group and incorporating the updated patient access scheme, was above £70,000 per QALY gained.
- Topotecan was dominated and excluded from the fully incremental analysis.
For women with platinum-resistant or refractory ovarian cancer, the committee agreed that:
- The ICER for topotecan compared with PLDH was approximately £450,000 per QALY gained.
- Paclitaxel was dominated by PLDH, but the committee noted that the costs and QALYs associated with paclitaxel are similar to those of PLDH and concluded that both could be considered cost effective.
- The additional analyses produced by the assessment group after appeal showing the impact of varying the drug cost for paclitaxel and PLDH did not change its conclusion that the costs and QALYs associated with paclitaxel and PLDH were similar.
How Has the New Cost-effectiveness Evidence That Has Emerged Since the Original Appraisals (Technology Appraisal 91 [TA91] and TA222) Influenced the Current (Preliminary) Recommendations?
For women with platinum-refractory or platinum-resistant disease, or who are allergic to platinum-based compounds, for whom PLDH and single-agent paclitaxel are considered inappropriate, topotecan is now not considered to be a cost-effective use of National Health Service (NHS) resources.
Method of Guideline Validation
External Peer Review
Description of Method of Guideline Validation
Consultee organisations from the following groups were invited to comment on the draft scope, Assessment Report and the Appraisal Consultation Document (ACD) and were provided with the opportunity to appeal against the Final Appraisal Determination (FAD).
- Manufacturer/sponsors
- Professional/specialist and patient/carer groups
- Commentator organisations (without the right of appeal)
In addition, individuals selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups were also invited to comment on the ACD.
Evidence Supporting the Recommendations
Type of Evidence Supporting the Recommendations
The type of evidence supporting the recommendations is not specifically stated.
The Appraisal Committee considered clinical and cost-effectiveness evidence submitted by the manufacturers and a review of this submission by the Assessment Group. The main clinical effectiveness evidence came from randomised controlled trials. For cost-effectiveness, the Appraisal Committee considered economic models submitted by one of the manufacturers and by the Assessment Group.
Benefits/Harms of Implementing the Guideline Recommendations
Potential Benefits
Appropriate use of paclitaxel and pegylated liposomal doxorubicin hydrochloride (PLDH) in women with recurrent ovarian cancer to increase response to treatment, survival, and quality of life
Potential Harms
The summaries of product characteristics list the following as the most common adverse reactions associated with:
- Paclitaxel: infection, myelosuppression, neutropenia, anaemia, thrombocytopenia, leukopenia, bleeding, mild hypersensitivity reactions, neurotoxicity, hypotension, diarrhoea, vomiting, nausea, mucositis, alopecia, arthralgia and myalgia
- Pegylated liposomal doxorubicin hydrochloride (PLDH): anorexia, nausea, stomatitis, vomiting, palmar–plantar erythrodysesthesia, alopecia, rash, asthenia, fatigue and mucositis
Qualifying Statements
Qualifying Statements
- The recommendations in this guidance represent the view of the National Institute for Health and Care Excellence (NICE) and was arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance are at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
- Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the National Health Service (NHS) Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Implementation of the Guideline
Description of Implementation Strategy
- Section 7(6) of the National Institute for Health and Care Excellence (NICE) (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, National Health Services (NHS) England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication.
- The Welsh Assembly Minister for Health and Social Services has issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 3 months of the guidance being published.
- When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraph above. This means that, if a patient has recurrent ovarian cancer and the doctor responsible for their care thinks that paclitaxel or pegylated liposomal doxorubicin hydrochloride (PLDH) is the right treatment, they should be available for use, in line with NICE's recommendations.
Implementation Tools
Foreign Language Translations
Mobile Device Resources
Patient Resources
Resources
For information about availability, see the Availability of Companion Documents and Patient Resources fields below.
Institute of Medicine (IOM) National Healthcare Quality Report Categories
Identifying Information and Availability
Bibliographic Source(s)
| National Institute for Health and Care Excellence (NICE). Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Apr 27. 61 p. (Technology appraisal guidance; no. 389). |
Adaptation
Not applicable: The guideline was not adapted from another source.
Date Released
2016 Apr 27
Guideline Developer(s)
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]
Source(s) of Funding
National Institute for Health and Care Excellence (NICE)
Guideline Committee
Appraisal Committee
Composition of Group That Authored the Guideline
Committee Members: Dr Jane Adam (Chair), Consultant Radiologist, Department of Diagnostic Radiology, St George's Hospital, London; Professor Iain Squire (Vice-Chair), Consultant Physician, University Hospitals of Leicester; Dr Graham Ash, Consultant in General Adult Psychiatry, Lancashire Care NHS Foundation Trust; Dr Jeremy Braybrooke, Consultant Medical Oncologist, University Hospitals Bristol NHS Foundation Trust; Dr Gerardine Bryant, GP, Swadlincote, Derbyshire; Professor Aileen Clarke, Professor of Public Health and Health Services Research, University of Warwick; Dr Justin Daniels, Consultant Paediatrician, North Middlesex University Hospital; Dr Andrew England, Senior Lecturer, Directorate of Radiography, University of Salford; Dr Rachel Hobson, Formulary Pharmacist, NHS Wiltshire CCG; Dr Mohit Misra, GP, Queen Elizabeth Hospital, London; Ms Sarah Parry, Clinical Nurse Specialist - Paediatric Pain Management, Bristol Royal Hospital for Children; Ms Pamela Rees, Lay member; Dr Paul Robinson, Medical Director, Merck Sharp & Dohme; Ms Ellen Rule, Director of Transformation and Service Redesign, Gloucestershire Clinical Commissioning Group; Mr Stephen Sharp, Senior Statistician, University of Cambridge MRC Epidemiology Unit; Dr Brian Shine, Consultant Chemical Pathologist, John Radcliffe Hospital, Oxford; Dr Eldon Spackman, Research Fellow, Centre for Health Economics, University of York; Mr David Thomson, Lay member; Dr John Watkins, Clinical Senior Lecturer, Cardiff University, Consultant in Public Health Medicine, National Public Health Service Wales; Professor Olivia Wu, Professor of Health Technology Assessment, University of Glasgow; Dr Nerys Woolacott, Senior Research Fellow, Centre for Reviews and Dissemination, University of York
Financial Disclosures/Conflicts of Interest
Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.
Guideline Status
This is the current release of the guideline.
This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer. London (UK): National Institute for Health and Clinical Excellence (NICE); 2005 May. 46 p. (Technology appraisal; no. 91).
This guideline meets NGC's 2013 (revised) inclusion criteria.
Guideline Availability
Available from the National Institute for Health and Care Excellence (NICE) Web site . Also available for download in ePub and eBook formats from the NICE Web site .
. Also available for download in ePub and eBook formats from the NICE Web site .Availability of Companion Documents
The following are available:
- Edwards SJ, Barton S, Thurgar E, Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for the treatment of recurrent ovarian cancer: a multiple technology appraisal. London (UK): BMJ-TAG; 2013. 574 p. Available from the National Institute for Health and Care Excellence (NICE) Web site .
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. Resource impact report. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Apr. 3 p. (Technology appraisal guidance; no. 389). Available from the NICE Web site .
Patient Resources
The following is available:
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. Information for the public. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Apr. 3 p. (Technology appraisal guidance; no. 389). Available in English and Welsh from the National Institute for Health and Care Excellence (NICE) Web site . Also available for download in ePub and eBook formats from the NICE Web site .
Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.
NGC Status
This NGC summary was completed by ECRI on June 1, 2006. This summary was updated by ECRI Institute on October 4, 2016.
The National Institute for Health and Care Excellence (NICE) has granted the National Guideline Clearinghouse (NGC) permission to include summaries of their Technology Appraisal guidance with the intention of disseminating and facilitating the implementation of that guidance. NICE has not verified this content to confirm that it accurately reflects the original NICE guidance and therefore no guarantees are given by NICE in this regard. All NICE technology appraisal guidance is prepared in relation to the National Health Service in England and Wales. NICE has not been involved in the development or adaptation of NICE guidance for use in any other country. The full versions of all NICE guidance can be found at www.nice.org.uk .
.Copyright Statement
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.
Disclaimer
NGC Disclaimer
The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.
.png)
No hay comentarios:
Publicar un comentario